Koss Olinger Consulting LLC Has $1.35 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Koss Olinger Consulting LLC lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 115.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 34,168 shares of the company's stock after purchasing an additional 18,298 shares during the period. Koss Olinger Consulting LLC's holdings in CRISPR Therapeutics were worth $1,345,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the 3rd quarter worth $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics during the third quarter valued at $43,000. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the fourth quarter valued at about $39,000. Western Pacific Wealth Management LP increased its position in CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares during the period. Finally, Spire Wealth Management increased its position in CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.10% of the company's stock.

Remove Ads

CRISPR Therapeutics Trading Up 0.1 %

Shares of CRISPR Therapeutics stock traded up $0.05 during trading on Friday, hitting $41.22. 1,539,000 shares of the stock were exchanged, compared to its average volume of 1,527,736. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $73.09. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of -9.43 and a beta of 1.77. The company has a fifty day moving average price of $43.09 and a 200-day moving average price of $45.37.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Truist Financial raised their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Citigroup lowered their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Royal Bank of Canada cut their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research note on Wednesday, February 12th. Finally, HC Wainwright reissued a "buy" rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.